India should eliminate tax on drugs for cancer treatment and for chronic and rare diseases, the chairperson of major ...
Biocon stock price is poised for a fresh breakout from its consolidation range of 320-395, following nearly three and a half ...
To make cancer care more affordable in price-sensitive India, Mazumdar-Shaw said, the government must also cut import duties ...
Biocon advanced 2.41% to Rs 397.20 after its board is scheduled to meet on Monday, 27 January 2025, to consider and approve the raising of funds on a private placement basis.
Bajaj Finserv Ltd. has garnered multiple buy recommendations from various analysts, all predicting an upward movement in the ...
CCI fines Goldman Sachs for undisclosed investment in Biocon, highlighting need for compliance with competition laws in ...
Syngene reported 18% YoY growth in Q3FY25 net profit. Revenue rose 11% YoY. EBITDA margin improved to 31.4%. Company expects ...
The market may extend its upward journey, but sustainability is the key to watch, given the elevated volatility. Below are ...
The market is expected to sustain range-bound trading, and the elevated volatility signals caution for bulls. Below are some ...
Shaw, chairperson of Biocon Ltd, urges the Indian government to eliminate taxes on drugs for cancer and chronic diseases.